Is oral chemotherapy prescription safe for patients? A cross-sectional survey

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 500-504

  Bourmaud, Aurélie ^a,b   Pacaut, C ^a   Melis, A ^a   Tinquaut, F ^a   Magne N ^a,b   Merrouche, Y ^a,b   Chauvin, F ^a,b,c  

^a Lucien Neuwirth Cancer Institute   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Education of patient; Oral chemotherapy; Patient adherence; Prescription practices; Safety monitoring; Side effects prevention

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; CANCER CENTER; CLINICAL TRIAL; HEALTH CARE QUALITY; MEDICATION COMPLIANCE; MULTICENTER STUDY; NEOPLASMS; PROSPECTIVE STUDY; QUESTIONNAIRE; STANDARDS;

ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES;

EID: 84893344110     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt553     Document Type: Article

References (14)

1. Weingart SN, Brown E, Bach PB et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008; 6(Suppl 3): S1-14.
2. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003; 7(6 Suppl): 5-9.
3. Partridge AH, Avorn J, Wang PS et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94(9): 652-661.
4. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs 2003; 7(2): 158-162.
5. Goodin S, Griffith N, Chen B et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract 2011; 7(1): 7-12.
6. Johnson PE, Chambers CR, Vaida AJ. Oncology medication safety: a 3D status report 2008. J Oncol Pharm Pract 2008; 14(4): 169-180.
7. Weingart SN, Flug J, Brouillard D et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007; 334(7590): 407.
8. Faithfull S, Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004; 8(Suppl1): S54-S62.
9. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003; 7(6 Suppl): 21-24.
10. Jacobson JO, Polovich M, Gilmore TR et al. Revisions to the 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract 2012; 8(1): 2-6.
11. Weingart SN, Li JW, Zhu J et al. US Cancer Center Implementation of ASCO/ Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract 2012; 8(1): 7-12.
12. Neuss MN, Polovich M, McNiff K et al. 2013 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract 2013; 9(2 Suppl): 5s-13s.
13. I national du cancer. Le traitement du cancer dans les établissements de santé en France en 2010: soins et vie des malades. Boulogne-Billancourt: Institut national du cancer 2010.
14. Ades F, Senterre C, de Azambuja E et al. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. Ann Oncol 2013; 24(11): 2897-2902.